← Back to all trials
Active Not Recruiting
NCT06425549
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
Conditions: Moderate to Severe Plaque Psoriasis
Sex: All
Ages: 6 Years – 17 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 176
Sponsor: UCB Biopharma SRL
Location: Ps0021 50162 Fountain Valley California
Summary
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \
Eligibility Criteria
Inclusion Criteria:
* Study participant must be 6 to \
Source: ClinicalTrials.gov (NCT06425549). StuddyBuddy aggregates publicly available trial information.
